Intec Pharma has named R. Michael Gendreau, M.D., Ph.D. chief medical officer. Dr. Gendreau comes with over 30 years of experience in the drug development and pharmaceutical industry.
"I am delighted to have Michael join our executive team. He is an extraordinarily talented individual who has extensive clinical trial experience and has helped obtain multiple FDA approvals," said Jeffrey A. Meckler, chief executive officer of Intec Pharma. "His knowledge and experience will meaningfully impact and move forward our Accordion Pill clinical programs."
Dr. Gendreau joins Intec after having founded a consulting firm providing strategic advice on the design and management of clinical programs, strategic planning, and technology assessments for emerging pharmaceutical, diagnostic, and medical device companies. He has served on various scientific advisory boards, executive strategic planning boards, and Data Safety Monitoring Boards. Prior to his consulting career, Dr. Gendreau served as chief medical officer at Cypress Bioscience, Inc., a clinical-stage biotech company developing therapies for central nervous system disorders.